98%
921
2 minutes
20
Herein, we describe novel iron-catalyzed transfer hydrogenation between alcohols and 1-(2-nitrophenyl)pyrroles for the synthesis of pyrrolo[1,2-α]quinoxalines. The tricarbonyl (η-cyclopentadienone) iron complex catalyzed the oxidation of alcohols and the reduction of nitroarenes, and the corresponding aldehydes and aniline were generated . The resulting Pictet-Spengler-type annulation/oxidation completed the quinoxaline structure formation. The protocol tolerated various kinds of functional groups and provided 29 samples of 4-substituted pyrrolo[1,2-α]quinoxalines. The developed method was also applied for the synthesis of additional polyheterocycles.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.joc.0c02145 | DOI Listing |
Org Biomol Chem
June 2025
College of Chemistry and Environment, Guangdong Ocean University, Zhanjiang 524088, China.
We have developed a visible-light-driven photocatalytic tandem reaction system to achieve the efficient synthesis of 2-sulfenylated pyrrolo[1,2-α]quinoxalines based on a radical addition-cyclization mechanism. Mechanistic studies show that the sulfur radical intermediates generated in the reaction system directly participate in the subsequent formation of C-S bonds. This strategy has opened up an efficient synthetic pathway for the precise synthesis of C2-sulfur-substituted heterocyclic compounds.
View Article and Find Full Text PDFBioorg Med Chem Lett
September 2025
Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China; Innovation Center for AI and Drug Discovery, East China Normal University, Shanghai 200062, China. Electronic address:
Bruton's tyrosine kinase (BTK) is a promising target for the treatment of B cell malignancies. Developing noncovalent BTK inhibitors is a promising strategy to address the treatment limitations of covalent BTK inhibitors including off-target toxicity and acquired resistance. Our group previously discovered a novel noncovalent BTK inhibitor S2 with pyrrolo[1,2-α]quinoxalin-4(5H)-one as the scaffold.
View Article and Find Full Text PDFJ Med Chem
April 2025
School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Bruton's tyrosine kinase (BTK) is a therapeutic target for B-cell-driven malignancies. Most of the approved covalent BTK inhibitors are associated with treatment limitations due to off-target toxicity and drug resistance. Developing noncovalent BTK inhibitors is a promising strategy to address unmet clinical needs.
View Article and Find Full Text PDFInt J Mol Sci
January 2025
Postovsky Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, S. Kovalevskoy Street, 22, Ekaterinburg 620137, Russia.
The synthetic approach based on a sequence of Buchwald-Hartwig cross-coupling and annulation through intramolecular oxidative cyclodehydrogenation has been used for the construction of novel 4-alkyl-4-thieno[2',3':4,5]pyrrolo[2,3-]quinoxaline derivatives. For the first time, these polycyclic compounds were evaluated for antimycobacterial activity, including extensively drug-resistant strains. A reasonable bacteriostatic effect against HRv was demonstrated.
View Article and Find Full Text PDFPLoS One
November 2024
Department of Medical Genetics, School of Basic Medicine, Jilin Medical University, Jilin, Jilin Province, P.R. China.
Background: Alzheimer's disease (AD) is a common elderly disorder characterized by cognitive decline. Endoplasmic reticulum (ER) stress has been implicated in various neurodegenerative diseases, including AD. Stem cell factor (SCF) performs its biological functions by binding to and activating receptor tyrosine kinase c-Kit.
View Article and Find Full Text PDF